S-1: Kestra Medical Tech IPO: $138.8M Raise, 52% Q3 Revenue Growth

Kestra Medical Technologies is launching a public offering of 5.5 million common shares to fund growth, reporting significant revenue increases and validating its ASSURE WCD's clinical benefits.

Summary

• Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on cardiovascular disease, with its primary product being the ASSURE WCD (wearable cardioverter defibrillator).
• The company is offering 5,500,000 common shares, with underwriters having an option to purchase an additional 825,000 shares, at an assumed public offering price of $26.98 per share.
• The offering is expected to generate approximately $138.8 million in net proceeds (or $159.7 million if the underwriters' option is fully exercised), which will be used to scale commercial operations, invest in device fleet, supply chain, revenue cycle management, R&D, and clinical development.
• The global WCD market reached $1.3 billion in 2023, with 85% of revenues from the U.S. The estimated annual addressable market is approximately $10 billion in the U.S. and $14 billion internationally.
• The ASSURE WCD, FDA approved in July 2021, has been worn by over 28,000 patients as of October 2025.
• Primary results from the ACE-PAS study (21,612 patients enrolled from November 2021 through July 2025) showed a 100% successful conversion rate for VT and VF events, an inappropriate-shock rate of 0.0065 per patient-month, and only 6% of patients experiencing a false alarm (compared to 46% for the competitor's device).
• Median daily use of the ASSURE WCD was over 23 hours per day, with one-third of patients continuing use beyond 90 days.
• Preliminary unaudited revenue for the three months ended October 31, 2025, is expected to be between $22.2 million and $22.6 million, a 52% increase from $14.7 million in the same period of 2024.
• Preliminary unaudited gross profit for the three months ended October 31, 2025, is expected to be between $11.0 million and $11.4 million, a 92% increase from $5.8 million in the same period of 2024, with gross margin improving to 50.0% from 39.6%.
• Loss from operations for the three months ended October 31, 2025, is expected to be between $31.6 million and $32.0 million, compared to $19.1 million for the same period in 2024, primarily due to increased personnel expenses.
• For the three months ended July 31, 2025, revenue was $19.4 million (52.0% growth year-over-year), and net loss was $25.8 million.
• For the fiscal year ended April 30, 2025, revenue was $59.8 million (115% growth year-over-year), and net loss was $113.8 million.
• The company had an accumulated deficit of $546.1 million as of July 31, 2025, and cash and cash equivalents of approximately $175 million as of October 31, 2025.

Sentiment

Score: 7

Explanation: The company demonstrates robust revenue growth and significant improvements in gross profit and margin, driven by a differentiated product with superior clinical outcomes and high patient compliance in an underpenetrated market. The capital raise provides substantial funding for continued expansion and market capture. While net losses are increasing due to growth investments and new investors face dilution, the strong operational performance, clear growth strategies, and validated product advantages present a compelling long-term investment opportunity for growth-focused investors.

Positives

• Strong revenue growth: 52% year-over-year for preliminary Q3 2025 (midpoint) and 52.0% for Q1 2025, and 115% for fiscal year 2025.
• Significant improvement in gross profit and gross margin: Preliminary Q3 2025 gross profit expected to increase 92% year-over-year, with gross margin improving to 50.0% from 39.6%.
• ASSURE WCD demonstrates superior clinical performance with a 100% successful conversion rate for VT and VF events and a low inappropriate-shock rate of 0.0065 per patient-month.
• The ASSURE WCD has a significantly lower false alarm rate (6% of patients) compared to the competitor's device (46%), enhancing patient comfort and compliance.
• High patient compliance is evidenced by a median daily use of over 23 hours per day for the ASSURE WCD.
• The company operates in a large and underpenetrated market, with an estimated $10 billion annual addressable market in the U.S. and $14 billion internationally.
• Broad payor coverage for the ASSURE WCD, covering over 290 million U.S. lives (approximately 90% of total available lives).
• Medicare reimbursement rate for WCDs is expected to increase by 2.8% beginning in 2026.
• Strategic investments in commercial organization, distribution, supply chain, and revenue cycle management create a high barrier to entry.
• FDA clearance of the ASSURE wearable ECG on May 7, 2024, provides extended monitoring capabilities for cardiac recovery.

Negatives

• The company has a history of net losses, reporting $25.8 million for Q1 2025 and $113.8 million for FY 2025.
• Accumulated deficit reached $546.1 million as of July 31, 2025.
• Loss from operations increased to an estimated $31.6 million-$32.0 million for preliminary Q3 2025, up from $19.1 million in Q3 2024, primarily due to increased personnel expenses for commercial growth.
• New investors in this offering will experience immediate dilution of $21.44 per share.
• The company is highly dependent on its ASSURE WCD for continued success.
• Reliance on a limited number of third-party suppliers and contract manufacturers could lead to supply shortages and price fluctuations.
• Billing for products is complex, requiring substantial time and resources.

Risks

• Limited operating history makes it difficult to evaluate the current business and its likelihood of success and viability.
• History of net losses with no assurance of achieving profitability, potentially requiring future equity or debt financing.
• High dependence on the ASSURE WCD for continued success.
• Commercial success relies on broad adoption by healthcare providers, hospitals, and patients.
• Failure to obtain and maintain broad coverage and adequate reimbursement levels from governmental authorities and health insurers could limit marketability and profitability.
• Inability to manage anticipated business growth could harm future revenue and operating results.
• Clinical study initiatives are complex, lengthy, expensive, and carry uncertain outcomes; future trials may not replicate positive results.
• Dependence on a limited number of third-party suppliers and contract manufacturers could lead to supply shortages and price fluctuations.
• Complexity of billing processes requires substantial time and resources.
• Competitors developing more effective products or gaining greater market acceptance could reduce commercial opportunities.
• Identified material weaknesses in internal control over financial reporting, which if not effectively remediated, could impair the ability to produce timely and accurate financial statements.
• Potential claims of intellectual property infringement by third parties could lead to costly, time-consuming, or unsuccessful litigation.
• Inadequate intellectual property protection could adversely affect the business.
• Changes in the regulatory environment may increase costs or difficulty in manufacturing, marketing, or distributing products, or obtaining approvals for future products.
• Failure to comply with healthcare and other governmental regulations could result in substantial penalties.
• Bain Capital has significant influence over the company, and its interests may conflict with those of other shareholders.
• Status as an emerging growth company and smaller reporting company may make common shares less attractive to investors.
• An active, liquid trading market for common shares may not be sustained.
• The share price may be volatile.
• Potential classification as a passive foreign investment company (PFIC) could result in adverse U.S. federal income tax consequences to U.S. Holders.
• A sale of a substantial number of common shares may cause the price to decline.
• Management will have broad discretion in the use of net proceeds from this offering.
• As a Bermuda company, it may be difficult for investors to enforce judgments against the company or its directors and executive officers in the U.S.
• Bermuda law differs from U.S. law and may afford less protection to shareholders.
• Regulatory limitations exist on the ownership and transfer of common shares in Bermuda.
• Anti-takeover provisions in the amended and restated bye-laws may discourage a change of control.
• Exclusive forum provisions may discourage lawsuits against directors and officers.
• The company has not historically paid cash dividends and does not expect to in the foreseeable future, limiting return on investment to share value appreciation.
• Future securities issuances could result in significant dilution to shareholders.

Future Outlook

The company intends to use the net proceeds from this offering to significantly scale its commercial organization, including hiring additional sales representatives and clinical care specialists. It plans continued investments in its device fleet, supply chain, and revenue cycle management capabilities. A portion of the proceeds will also fund research and development and clinical development to support product innovation and build clinical evidence. The company aims to continue payor engagement to broaden coverage and increase reimbursement, and to innovate its system and bolster its digital healthcare platform. International expansion is a key strategy, with plans to pursue CE Mark approval in Europe and strategically commercialize in selected international countries within the next three years, initially focusing on Western Europe. The company also intends to pursue adjacent markets with new product offerings and differentiated services.

Management Comments

• We believe our Cardiac Recovery System platform addresses serious unmet needs in the cardiac patient population and has the potential to disrupt and grow the market which has been limited to a single solution for more than 20 years.
• We believe we offer the most comprehensive and cohesive platform, with digital solutions and services that are seamlessly integrated with our ASSURE WCD, meaningfully differentiating our Cardiac Recovery System platform from the only other commercially available WCD.
• We believe our significant investments in infrastructure create a high barrier to entry that will help us protect and grow our market share.

Industry Context

The wearable cardioverter defibrillator (WCD) market has been historically limited to a single solution for over 20 years, leading to underutilization of this therapy (reaching only 14% of eligible U.S. patients in 2023). Kestra Medical Technologies' ASSURE WCD is positioned as a next-generation device designed to overcome the limitations of the incumbent product, such as high false alarm rates, poor wearability, and limited connectivity. The company aims to disrupt and grow this market, which is also expanding due to a rapidly growing heart failure population. The increasing Medicare reimbursement rates reflect growing recognition and support for WCD therapy as a life-saving solution.

Comparison to Industry Standards

• The ASSURE WCD's false alarm rate is 6% of patients, significantly lower than the 46% reported for the competitor's device.
• The ASSURE WCD delivers a 170 joule shock, which is higher than the 150 joule shock delivered by the competitor device, potentially better serving patients with higher defibrillation thresholds.
• The ASSURE WCD offers a minimum defibrillation capacity of 25 shocks, providing a significant safety buffer for patients experiencing multiple cardiac events.
• The ASSURE WCD's median daily use of over 23 hours per day demonstrates enhanced patient comfort and compliance compared to the limitations of the legacy device.

Corporate Governance

Related Party Transactions

• Bain Capital, which will own approximately 47.5% of common shares after the offering, has significant influence over the company, and its interests may conflict with those of other shareholders.
• Warrants were issued to Kennedy Lewis Capital Partners Master Fund II LP and Perceptive Credit Holdings IV, LP prior to the IPO, and new warrants were issued to them by Kestra Medical Technologies, Ltd. in connection with the IPO.
• Affiliates of Endeavour Entities beneficially own 2,646,899 shares (5.1% prior to offering).

Stakeholder Impact

• Shareholders: Potential for dilution from the offering, but also potential for growth from increased capital. Risk of share price volatility. Bain Capital's significant influence may impact corporate decisions.
• Patients: Benefit from improved comfort and compliance of the ASSURE WCD, enhanced safety through integrated digital solutions, and extended monitoring capabilities with the ASSURE wearable ECG.
• Healthcare Providers: Equipped with actionable insights from the Kestra CareStation remote patient data platform to support timely and informed care decisions.
• Employees: Increased headcount to support commercial growth, with equity incentive plans in place.
• Creditors: The company's term loan limits its ability to pay dividends or make other distributions.

Next Steps

• Scale up the commercial organization through hiring additional sales representatives, sales team leadership, and clinical care specialists.
• Continue investments in the fleet of devices, supply chain, and revenue cycle management capabilities.
• Further fund research and development and continued clinical development costs to support product innovation and fund trials.
• Continue payor engagement to broaden coverage and increase reimbursement.
• Innovate the system and bolster the digital healthcare platform and data management capabilities.
• Drive gross profit expansion and operating leverage.
• Pursue expansion in international markets, with an initial focus on Western Europe and a goal to obtain regulatory approvals within the next three years.
• Strategically pursue adjacent markets with new product offerings and differentiated services.

Key Dates

Recommendation

The company is demonstrating robust revenue growth (52% Q3, 115% FY25) and significant gross margin expansion (50% in Q3 2025). Its core product, the ASSURE WCD, shows strong clinical differentiation with superior patient compliance and significantly lower false alarm rates compared to its sole competitor, addressing a large and underpenetrated market. The follow-on offering will provide substantial capital ($138.8M-$159.7M) to fund aggressive commercial expansion, R&D, and international market entry, positioning the company for continued market share capture and long-term growth. While the company is currently unprofitable and new investors face dilution, the strong operational performance, clear growth strategies, and validated product advantages suggest a compelling long-term investment opportunity for growth-focused investors.

Keywords

Wearable cardioverter defibrillator, WCD, Sudden Cardiac Arrest, SCA, Cardiac Recovery System, Medical Device, Digital Health, Patient Monitoring, Defibrillation, Heart Failure, LVEF, FDA Approval, IPO, Kestra Medical Technologies, ASSURE WCD, Healthcare Technology, Medical Technology, Public Offering